Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > BAG HOLDERS CONSTANTLY BEGGING

<< Previous

Bullboard Posts

Next >>

Comment by Newinvestor68on Jun 05, 2020 10:35pm

148 Views

Post# 31119304

RE:RE:RE:RE:BAG HOLDERS CONSTANTLY BEGGING

In Canada pennies are no longer produced because they serve no purpose. That is the same of Pennythetools comments. Just ignore it and it will go away. It has some interest in the company, who knows and cares what that is. Let's just all ignore it and it's comments to take its power away.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property